[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemia-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemia-stroke":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,73,99,141,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100639799","phase-1-investigating-central-contributions-to-fatigue-using-non-invasive-brain-stimulation-100639799",false,"NCT07613970","Investigating Central Contributions to Fatigue Using Non-invasive Brain Stimulation","Investigating the Causal Contribution of Neural Oscillations to Neuromuscular Fatigue After Stroke Using tACS","Inclusion Criteria:\n\nFirst-ever stroke\n\n≥18 years Subacute phase: 1 week to 6 months post-stroke Quadriceps (hemiplegic side) strength ≤3\u002F5 (Medical Research Council (MRC)) Montreal Cognitive Assessment (MoCA) ≥21\n\nExclusion Criteria:\n\nHistory of a previous stroke Severe spasticity (Modified Ashworth Scale (MAS) 3-4 in quadriceps\u002Fhamstrings) Other neurological, motor, musculoskeletal, or orthopedic conditions affecting trunk stability and lower limb mobility Non-cerebral strokes (e.g., brainstem, cerebellar), or dementia (MoCA ≤20) Current or former athletes. Athletes are defined as individuals who participated in organized competitive sports and engaged in structured training ≥3 sessions per week for ≥1 year within the 5 years preceding stroke Contraindications for tACS (e.g., presence of a deep brain stimulator, pacemaker, head wound, etc.).",true,"ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this interventional study is to understand the contribution of the central components to the manifestation of neuromuscular fatigue in stroke survivors. The study will include adults with a first-ever stroke in the subacute phase.\n\nThe main question it aims to answer:\n\n• How does the brain activity contribute to the manifestation of neuromuscular fatigue in stroke survivors?\n\nResearchers will compare stroke participants receiving active vs sham tACS in a single session before the fatiguing contractions to determine whether central changes can influence fatigue onset\u002Fprogression.\n\nParticipants will:\n\n* Perform repeated leg muscle contractions until fatigue while seated in an experimental setup\n* Receive either active or sham tACS for 20 minutes before the fatiguing contractions.\n* Wear non-invasive sensors to record brain activity (EEG) and muscle activity (EMG) during the task\n* Complete the study during a single experimental session in which fatigue-related changes will be measured throughout the task",[28,29,30,31],"Stroke","Cerebrovascular Accident (CVA)","Ischemia Stroke","Hemorrhage Stroke",[33,34,35,36,37,38,39],"fatigue","electroencephalography","EEG","electromyography","EMG","transcranial alternating current stimulation","tACS","NOT_YET_RECRUITING","2026-05-21",{"date":43,"type":44},"2026-05-29","ACTUAL",{"date":46,"type":21},"2026-09-01",{"date":48,"type":21},"2029-10-31",{"name":50,"class":51},"Vrije Universiteit Brussel","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":72,"locationsCount":4},"100638548","studying-fatigue-and-movement-after-stroke-100638548","NCT07594938","Studying Fatigue and Movement After Stroke","Exploring Neuromuscular Fatigue in Stroke Survivors: Understanding Central-Peripheral Interaction","Inclusion Criteria:\n\nStroke survivors will be recruited from Brussels University Hospital (Brussels, Belgium). Patients who have a first-ever stroke, ≥18 years, subacute phase: 1 week to 6 months post-stroke, quadriceps (hemiplegic side) strength ≤3\u002F5 (Medical Research Council (MRC)), and Montreal Cognitive Assessment (MoCA) ≥21 will be included.\n\nExclusion Criteria:\n\nExclusion criteria include a history of a previous stroke, severe spasticity (Modified Ashworth Scale (MAS) 3-4 in quadriceps\u002Fhamstrings), other neurological, motor, musculoskeletal, or orthopedic conditions affecting trunk stability and lower limb mobility, non-cerebral strokes (e.g., brainstem, cerebellar), or dementia (MoCA ≤20), and current or former athletes. Athletes are defined as individuals who participated in organized competitive sports and engaged in structured training ≥3 sessions per week for ≥1 year within the 5 years preceding stroke. Control participants will be excluded if they meet the same exclusion criteria.",{"count":20,"type":21},"1 Day","OBSERVATIONAL","The goal of this observational study is to learn how neuromuscular fatigue develops after stroke and how changes in brain activity, muscle activity, and their interaction contribute to reduced motor performance in stroke survivors compared to healthy individuals. The study will include adults with a first-ever stroke in the subacute phase and age-matched healthy volunteers.\n\nThe main questions it aims to answer are:\n\n* How does neuromuscular fatigue develop during repeated muscle contractions after stroke compared to healthy individuals?\n* How do brain activity, muscle activity, and brain-muscle interaction change during fatigue after stroke?\n\nResearchers will compare stroke participants and healthy control participants to determine whether fatigue-related changes are more strongly associated with altered brain activity, altered muscle activity, or disrupted brain-muscle communication after stroke.\n\nParticipants will:\n\n* Perform repeated leg muscle contractions until fatigue while seated in an experimental setup\n* Wear non-invasive sensors to record brain activity (EEG) and muscle activity (EMG) during the task\n* Complete the study during a single experimental session in which fatigue-related changes will be measured throughout the task",[28,64,30,31],"Cerebro-vascular Accident",[33,34,35,36,37,66],"stroke","2026-05-18",{"date":69,"type":44},"2026-05-19",{"date":46,"type":21},{"date":48,"type":21},{"name":50,"class":51},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100632656","phase-2-intra-arterial-methylprednisolone-after-endovascular-thrombectomy-100632656","NCT07516522","Intra-arterial Methylprednisolone After Endovascular Thrombectomy","Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18-80 years old;\n* The time from onset to randomization was within 24 hours;\n* Large vessel occlusive stroke in the anterior circulation confirmed by CTA\u002FMRA\u002FDSA (Including intracranial segment of internal carotid artery, M1 or M2 segment of middle cerebral artery) and the vessel responsible for the signs and symptoms of acute ischemic stroke;\n* NIHSS score \\>= 6 points\n* Alberta Stroke Program Early Diagnosis (ASPECTS) score of NCCT \\>=3;\n* Successful endovascular thrombectomy (eTICI 2b50-3)\n* Written informed consent signed by patients or their family members\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by computed tomography (CT) or magnetic resonance imaging (MRI);\n* Prestroke mRS score \\>= 2\n* pregnant or lactating patients\n* Allergy to iodinated contrast media, or methylprednisolone sodium succinate\n* Participating in other clinical research;\n* Inherited\u002Facquired hemorrhagic diathesis (coagulation factor deficiency) or oral anticoagulation with international normalized ratio (INR) \\>1.7\n* History of major bleeding within the past 1 month (gastrointestinal\u002Fgenitourinary hemorrhage)\n* Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m\\^2 or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl));\n* Terminal illness with life expectancy \\\u003C6 months;\n* Blood glucose \\\u003C 2.8mmol\u002FL (50mg\u002Fdl) or \\> 22.2mmol\u002FL (400mg\u002Fdl);\n* Intracranial aneurysm, arteriovenous malformation, or space-occupying brain tumor with mass effect on imaging\n* Active systemic infectious disease\n* Anticipated inability to complete follow-up\n* Intraoperative DSA showed vascular perforation, dissection, and contrast extravasation;\n* Puncture to recanalization was more than 90 minutes;\n* Total thrombectomy passes \\>3","80 Years",{"count":83,"type":21},210,[25],"The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg\u002Fkg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 178 patients (n=89 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 15% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=210 patients (n=105 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.",[30,87,88],"Thrombectomy","Large Vessel Occlusion","RECRUITING","2026-03-31",{"date":92,"type":44},"2026-04-08",{"date":90,"type":44},{"date":95,"type":21},"2027-12-31",{"name":97,"class":51},"Tang-Du Hospital",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":98},"100611166","phase-2-minocycline-in-stroke-study-at-maimonides-100611166","NCT07237048","Minocycline in Stroke Study at Maimonides","Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial","\\* Inclusion criteria\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Age \\>\u002F=18\n2. NIHSS 5-20 \\*National Institutes of Health Stroke Scale\\*\n3. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO \\*(World Health Organization) \\* guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed\n4. The onset of neurological symptoms less than 24 hours\n\n   * Exclusion criteria\n\nAn individual who meets any of the following criteria is excluded from participation in this study:\n\n1. Clinically stroke is not suspected\n2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline\n3. Pregnancy or suspected pregnancy or breastfeeding\n4. Previous history of intolerance to Minocycline\n5. Acute or chronic renal failure (stage III with GFR \\*(Glomerular Filtration Rate) \\* or Creatinine threshold)\n6. Any patients with contraindications to undergo CT (Computed Tomography) \u002F MRI (Magnetic Resonance Imaging)\n7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission\n8. Pre-existing infectious disease requiring antibiotics\n9. Inability to tolerate enteral medications\u002Ffeeds\n10. Patient\u002F family refusal",{"count":107,"type":21},1164,[25,109],"PHASE3","The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.\n\nThe main questions it aims to answer are:\n\n1. Does Minocycline improve \\*National Institutes of Health Stroke Scale\\* (NIHSS) scores at hospital discharge and 90 days post-stroke?\n2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\\*Modified Rankin Scale\\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?\n\nResearchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.\n\nParticipants will:\n\n1. Be randomly assigned by block to receive either:\n\n   Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only\n2. Undergo neurological assessments using NIHSS \\*National Institutes of Health Stroke Scale\\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke\n3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses\n\nNIHSS: \\*National Institutes of Health Stroke Scale\\*, which is stroke severity scale,\n\nmRS: \\*Modified Rankin Scale\\*, which is stroke disability scale",[28,30,112,113,114,115,116],"Hemorrhagic Strokes","Mortality","Morbidity","Cerebrovascular Accident (Stroke)","Intracerebral Haemorrhage (ICH)",[118,119,120,121,122,123,124,125,126,127,114,113,128,129,130,131],"Minocycline","Acute Stroke","Neuroprotection","Ischemic Stroke","Hemorrhagic Stroke","NIH Stroke Scale","Modified Rankin Scale (mRS)","Stroke Recovery","Stroke Treatment","Stroke Outcomes","Intravenous Thrombolysis","Mechanical Thrombectomy","Hemorrhagic Transformation","Oral antibiotic","2026-03-18",{"date":134,"type":44},"2026-03-19",{"date":136,"type":44},"2026-02-02",{"date":138,"type":21},"2028-12",{"name":140,"class":51},"Joyce Chen",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":152,"conditions":153,"keywords":158,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100619335","nursing-health-education-to-improve-functionality-and-quality-of-life-after-ischemic-stroke-100619335","NCT07343284","Nursing Health Education to Improve Functionality and Quality of Life After Ischemic Stroke","Effect of a Nursing Intervention Based on Health Education on Functionality, Depression Symptoms, and Quality of Life in Patients With Ischemic Stroke: A Quasi-Experimental, Longitudinal, and Prospective Clinical Trial","Inclusion Criteria:\n\n* Anterior or posterior cerebral occlusion\n\nExclusion Criteria:\n\n* Intracranial hemorrhage\n* Pregnancy\n* Cognitive incapacity for participation\n* Refusal to participate in the study and administer the questionnaires.",{"count":149,"type":21},70,[151],"NA","This study is titled \"Effect of a Nursing Intervention Based on Health Education on Functionality, Depression Symptoms, and Quality of Life in Patients with Ischemic Stroke.\" It is a quasi-experimental, longitudinal, prospective clinical trial that will beconducted with patients who have suffered an ischemic stroke and were treated in the neurology unit of the Lucus Augusti University Hospital, the same center where this study will take place.\n\nThe primary objective of the study is to determine the effect of a nursing intervention based on health education on quality of life and depression symptoms in individuals who have experienced an ischemic stroke.\n\nTo achieve this objective, variables such as cognitive status, depression symptoms, autonomy and ability to perform basic activities of daily living, neurological deficits, and quality of life will be assessed.\n\nRegarding the total number of subjects to be studied, according to the Stroke Atlas in Galicia published by the Spanish Society of Neurology in 2018, the autonomous community of Galicia had a population of 2,701,819 inhabitants. Applying an incidence rate of 187.4 cases per 100,000 inhabitants according to the IBERICTUS study, an estimated 5,064 new stroke cases occur each year in Galicia. The province of Lugo had 324,842 inhabitants as of January 1, 2024, according to the INE; therefore, applying the same incidence rate, an estimated 609 new stroke cases occur per year. Considering the proportion of ischemic strokes compared to other types of strokes (80:20), the estimated number of ischemic stroke cases in Lugo would be 487. The representative sample size of stroke patients in the province of Lugo would be 70 patients, with 35 patients receiving the intervention and 35 serving as controls.\n\nIndependent Variables:\n\nSociodemographic: sex, age, event date. Clinical: stroke type, treatment modality (rt-PA or thrombectomy), falls, pain, pressure ulcers, aspiration, pneumonia, dysphagia, vital signs.\n\nHealth education: received vs. not received.\n\nDependent Variables:\n\nCognitive status (MMSE). Depression symptoms (BDI). Autonomy and ADL performance (Barthel Index). Neurological deficits (NIHSS). Quality of life (European Quality of Life Scale).\n\nInstruments Mini-Mental State Examination (MMSE) Beck Depression Inventory (BDI) Barthel Index NIH Stroke Scale (NIHSS) Visual Analogue Scale (VAS) European Quality of Life Scale (EQLS)",[30,154,155,156,157],"Post-stroke Depression","Post-stroke","Quality of Life","Health Education",[159,160,161,162,163],"Ischemic stroke","Nursing","Depression","Health education","Quality of life","2026-01-07",{"date":166,"type":44},"2026-01-15",{"date":168,"type":21},"2026-06-01",{"date":170,"type":21},"2027-12-01",{"name":172,"class":51},"University of Santiago de Compostela",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":182,"studyType":61,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100563346","balloon-expandable-des-for-icas-registry-study-bdes-icas-registry-100563346","NCT06614972","Balloon-expandable DES for ICAS Registry Study (BDES-ICAS Registry)","Clinical Outcome of Balloon-Expandable Drug-Eluting Stenting For Patients With Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Real-World Registry Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. According to clinical and angiographic evidence, symptomatic intracranial arteries stenosis within 3 months include vertebral artery V4 segment or internal carotid artery C2-C7 segment, and the degree of diseased arterial stenosis is between 70%\\~99% (WASID method).\n3. Patients have more than 1 episode of symptoms including stroke or transient ischemia attack (TIA) after intensive medical treatment (including antiplatelet therapy, antihypertensive, hypoglycemic and lipid-lowering treatments).\n4. Patients have at least 1 risk factor for intracranial atherosclerosis, including previous or existing hypertension, hyperlipidemia, diabetes mellitus, smoking, alcohol consumption, obesity, underlying heart disease, family history of atherosclerotic vascular disease, hyperhomocysteinemia and so on.\n5. Baseline mRS score ≤3.\n6. Patient or guardian signs informed consent.\n\nExclusion Criteria:\n\n1. Patients who cannot receive dual antiplatelet therapy due to existing diseases or with server coagulation dysfunction, uncontrolled serious infections, serious systemic diseases, uncontrollable hypertension and other conditions are not suitable for surgery.\n2. Patients with aneurysm that cannot be treated in advance or at the same time or are not suitable for surgery.\n3. Gastrointestinal disease with active bleeding.\n4. Myocardial infarction or massive cerebral infarction within 2 weeks.\n5. Patients with known severe allergies or contraindications to heparin, rapamycin, anesthesia and contrast media.\n6. Life expectancy \\<12 months.\n7. According to the judgement of the investigator, other situations that are not suitable for enrollment.",{"count":181,"type":21},520,"5 Years","To study the clinical outcomes after implantation of balloon-expandable drug-eluting stents in patients with symptomatic intracranial atherosclerotic stenosis in prevention of composite event of any stroke and death within 30 days and ischemic stroke in the territories of the responsible artery from 31 days to 1-year.",[185,186,30],"Atheroscleroses, Cerebral","Intracranial Atherosclerosis",[188,189],"Intracranial Atherosclerosis Stroke","Drug-eluting stent","2024-09-23",{"date":192,"type":44},"2024-09-26",{"date":194,"type":21},"2024-09-30",{"date":196,"type":21},"2030-09-30",{"name":198,"class":51},"RenJi Hospital"]